Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
22 juin 2020 16h01 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
22 juin 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
18 juin 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
09 juin 2020 07h30 HE
|
Revolution Medicines, Inc.
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) --...
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
19 mai 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
14 mai 2020 16h05 HE
|
Revolution Medicines, Inc.
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung Cancers Preclinical...
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
29 avr. 2020 08h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
18 mars 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
09 mars 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...